Recomendações no manejo das complicações infecciosas no transplante de células-tronco hematopoéticas

Garnica, Márcia; Machado, Clarisse Martins; Cappellano, Paola; Carvalho, Viviane V. H.; Nicolato, Andrea; Cunha, Clóvis Arns da; Nucci, Márcio

doi:10.1590/s1516-84842010005000026

Cited by 9 publications

(15 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estima-se que a infecção da corrente sanguínea corresponda à variação de 10 a 15% de todas as infecções hospitalares. Entretanto, apesar de não ser a principal infecção hospitalar, esta contribui para o prolongamento do tempo de internação, acarretando importante ônus para as instituições de saúde 26 , além dos evidentes prejuízos para os pacientes, uma vez que a infecção em receptores de TCTH está relacionada a altas taxas de morbidade e mortalidade 27 .…”

Section: Metodologiaunclassified

Cateter de Hickman no transplante de células-tronco hematopoéticas: implante cirúrgico, retirada e assistência de enfermagem

Rodrigues¹,

Garbin

Castanho

et al. 2015

Rev. enferm. UERJ

View full text Add to dashboard Cite

Section: Metodologiaunclassified

Cateter de Hickman no transplante de células-tronco hematopoéticas: implante cirúrgico, retirada e assistência de enfermagem

Rodrigues¹,

Garbin

Castanho

et al. 2015

Rev. enferm. UERJ

View full text Add to dashboard Cite

“…Although no serology is performed before the transplant, a prior history of HZ has a strong relationship with the positivity of the serologic testing 15 . In this specific case, only one of the eight patients who had had HZ prior to the transplant suffered a recurrence of the disease.…”

Section: Discussionmentioning

confidence: 90%

“…Previous studies have shown that the results of this measure may be negligible, since the vaccine is not recommended within the first year after transplant (live attenuated vaccine) and the incidence of VZV is rare after this period 15 . More recent studies, however, using immunization two months after HSCT with an adjuvant subunit of varicella-zoster virus glycoprotein E, have shown it to be a reasonable strategy to reduce HZ in autologous HSCT patients 4 …”

Section: Discussionmentioning

confidence: 99%

Herpes zoster after autologous hematopoietic stem cell transplantation

Santos

Souza

Atalla

et al. 2016

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

BackgroundThe autologous hematopoietic stem cell transplantation procedure involves immunosuppression of the patient. Thus, the patient has an elevated risk for several diseases, such as infections with the varicella-zoster virus. Prevention protocols have been proposed based on the use of acyclovir from the first day of conditioning, and maintaining this drug for 30–100 days after the procedure or for as much as one year. The objective of this work was to evaluate the incidence of herpes zoster after autologous transplantations related to the early suspension of acyclovir.MethodsA retrospective study was carried out based on the collection of data from 231 medical records of transplant patients in the Bone Marrow Transplant Unit of the teaching hospital of the Universidade Federal de Juiz de Fora in the period between 2004 and 2014.ResultsFourteen (6.1%) patients had herpes zoster in the post-transplant period on average within six months of the procedure. Patients with multiple myeloma (64.3%) were the most affected. There was a statistically significant difference in the age of the patients, with older individuals having a greater chance of developing the infection (p-value = 0.002). There were no significant differences for the other variables analyzed.ConclusionThe early suspension of acyclovir can be safe in patients who receive autologous hematopoietic stem cell transplants. However some groups may benefit from extended prophylaxis with acyclovir, particularly older patients and patients with multiple myeloma.

show abstract

“…[11][12] At this stage, mucositis can be intensified causing pain and discomfort, making speech and swallowing difficult. These symptoms have disabling potential and weaken the patient, negatively interfering in their QoL.…”

Section: Introductionmentioning

confidence: 99%

Qualidade De Vida Nos Primeiros Seis Meses Pós-Transplante De Células-Tronco Hematopoéticas

Marques

Proença

Machado

et al. 2017

Texto contexto - enferm.

View full text Add to dashboard Cite

Objective: to evaluate the quality of life of adult patients with hematologic cancers undergoing hematopoietic stem cell transplantation in the first six months and comparing the transplant modalities.Method: an observational longitudinal study with 55 participants followed during pre-transplantation, after 100 days, and after 180 days in a reference teaching hospital for this treatment in Brazil. Two international instruments were used for the evaluation, both validated and translated into Portuguese (Brazil): The Quality of Life Questionnaire-Core 30 and the Functional Assessment Cancer Therapy-Bone Marrow Transplantation. Results:The results showed that the average age of the participants was 36 years old; 65% (n=36) had a diagnosis of leukemia, and 71% (n=39) underwent allogeneic transplantation. Regarding the Quality of Life Questionnaire-Core 30 instrument, social function and fatigue were significant results, while the functional well-being and treatment outcome evaluation index for the Functional Assessment Cancer Therapy-Bone Marrow Transplantation questionnaire had significant domains between the first and the second stage.Conclusions: despite transplantation being a complex and aggressive treatment, it can be noticed that patients generally perceive their quality of life as satisfactory throughout the therapeutic process. The findings of the study show that a significant portion (69% of patients) recover their quality of life after the first six months of treatment. DESCRIPTORS: QUALIDADE DE VIDA NOS PRIMEIROS SEIS MESES PÓS-TRANSPLANTE DE CÉLULAS-TRONCO HEMATOPOÉTICAS CALIDAD DE VIDA EN LOS PRIMEROS SEIS MESES POST-TRANSPLANTES DE CÉLULAS-TRONCO HEMATOPOÉTICAS RESUMENObjetivo: evaluar la calidad de vida de los pacientes adultos con cáncer hematológico sometidos al transplante de células madre hematopoyéticas en los primeros seis meses y comparar entre las modalidades de trasplante.Método: estudio observacional, longitudinal, con 55 participantes, acompañados en las etapas pre-trasplante, después de 100 días y después de 180 días, en un hospital de enseñanza, referencia en Brasil para este tratamiento. Para la evaluación se utilizaron dos instrumentos internacionales, ambos validados y traducidos a la lengua portuguesa (

show abstract

Recomendações no manejo das complicações infecciosas no transplante de células-tronco hematopoéticas

Cited by 9 publications

References 135 publications

Cateter de Hickman no transplante de células-tronco hematopoéticas: implante cirúrgico, retirada e assistência de enfermagem

Cateter de Hickman no transplante de células-tronco hematopoéticas: implante cirúrgico, retirada e assistência de enfermagem

Herpes zoster after autologous hematopoietic stem cell transplantation

Qualidade De Vida Nos Primeiros Seis Meses Pós-Transplante De Células-Tronco Hematopoéticas

Contact Info

Product

Resources

About